Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11299MR)

This product GTTS-WQ11299MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11299MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7902MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ294MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ9512MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J2898A
GTTS-WQ13997MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ2625MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ5030MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ316MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ5257MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CB-6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW